Simsen Diagnostics Partners with One-carbon Therapeutics for Groundbreaking ODIN Cancer Trial
Simsen Diagnostics, a leader in ultra-sensitive analysis of nucleic acids, today announced a collaboration with One-carbon Therapeutics, a Swedish pharmaceutical company, for their groundbreaking ODIN trial. This first-in-human, first-in-class Phase 1/2 clinical trial will evaluate TH9619, a novel MTHFD1/2 inhibitor, in patients with selected solid cancers.
One-carbon selected Simsen Diagnostics after a thorough vendor evaluation process. Simsen will deploy its highly sensitive Simsen® Personal solution, powered by the proprietary SiMSen-Seq platform, to monitor circulating tumor DNA (ctDNA) throughout the trial. Simsen® Personal allows for personalized tracking of tumor-specific genetic variations over time using simple blood draws. This approach offers the potential to detect minimal residual disease, monitor treatment response, identify relapse earlier, and deepen the understanding of disease evolution.
The primary objective of the ODIN trial is to determine the optimal dose regimen for TH9619 through dose escalation. The precise and reliable data generated by Simsen® Personal will be instrumental in guiding this process and evaluating the therapeutic potential of TH9619.
“We are thrilled to partner with One-carbon Therapeutics on this important clinical trial,” said Dr. Stefan Filges, Simsen’s CTO. “The ODIN trial represents a significant step forward in the development of innovative cancer treatments, and we are confident that our services will provide valuable insights to support One-carbon’s research.”
This collaboration leverages the combined expertise and cutting-edge technologies of both Simsen Diagnostics and One-carbon Therapeutics, aiming to accelerate the development of more effective and personalized cancer therapies.
About Simsen Diagnostics:
Simsen Diagnostics is a Swedish precision diagnostics company, transforming minute traces of DNA into actionable answers for clinical challenges. From its base at AstraZeneca’s BioVentureHub in Gothenburg, Simsen delivers ultra-sensitive sequencing and AI-powered bioinformatics for oncology (ctDNA), enabling cancer clinics, pharmaceutical partners, and researchers to detect and act on signals previously undetectable. By combining high sensitivity, robust data security, and user-friendly solutions, Simsen Diagnostics is driving progress in cancer care, with the goal of providing clear molecular answers – from trace to truth. https://simsendiagnostics.com/
About One-carbon Therapeutics:
One-carbon Therapeutics AB is tackling the most difficult to treat cancers, inflammation and autoimmune diseases by targeting the disease specific one-carbon metabolism pathway, representing a novel way of attacking the DNA damage response (DDR). Co-founded in 2020 by the Helleday Laboratory, with over 20 years of experience in DNA damage response (DDR) biology, we are taking the previous success of discovering the synthetic lethal concept for the treatment of BRCA mutated cancer with PARP inhibitors to a new level; attacking difficult to treat cancers using synthetic lethality in the one-carbon pathway to target the DNA damage response for treatment of cancer and inflammation. https://one-carbon.com
Contact:
Stefan Filges
CTO, Simsen Diagnostics
stefan@simsendiagnostics.com
